Albion News

Healios, the digital therapy company for mental health, has raised £2.2m ($3m) in its latest funding round, led by investors Albion Capital and Spice Capital. Founded in 2013, Healios empowers young patients and families affected by mental illness and neurodevelopmental conditions through combining the use of technology with specialised clinician expertise and evidence-based clinical tools. Utilising its unique digital platform, Healios enables the efficient delivery of family-centric care, delivering a revolutionary interactive experience across multiple family members. Its technology-driven... read more
Koru Kids
Koru Kids has announced a seed funding round totalling £3.5m The round was led by leading tech VCs Forward Partners and Albion Capital JamJar Investments and several high profile angel investors also took part 30% month on month growth as demand from parents for its unique model blooms Koru Kids, the London based startup on a mission to fix the broken after-school childcare landscape, has successfully completed a raise of £3.5m in what was an oversubscribed seed round. The ambitious business, which is growing at a rate of 30% monthly, is taking on the UK’s £11bn childcare market by... read more
Huge congratulations to Vishal Marria, CEO and founder of Quantexa for winning the Developing Entrepeneur award, in recognition of outstanding personal and company achievements and Rachel Carrell, founder of Koru Kids for being a finalist in the Female Entrepreneur and Social Entrepeneur categories! Last night at The 2018 Enterprise Awards in associaiton with WCIT.  read more
M12 Award
Hazy, the data anonymisation software developer formerly known as Anon AI, has won M12’s Innovate AI award, receiving a $1million investment from M12 in partnership with Notion. Innovate AI is a global competition launched by M12, formerly Microsoft Ventures, to recognise and award capital to high-potential AI and machine learning start-ups. Ten finalists each in North America, Europe and Israel competed in a live pitch-off where their ideas were evaluated by a panel of experts from Microsoft and a local venture capital manager. The investment awarded to Hazy adds to the £340,000 pre-seed... read more
The UCL Technology Fund (UCLTF), UK Innovation & Science Seed Fund (UKI2S), alongside support from Innovate UK, have invested in UCL spinout company Glialign Ltd, which is developing a novel cell therapy for peripheral nerve repair.  Hundreds of thousands of people every year are affected by severe peripheral nerve damage, resulting in paralysis and loss of sensation, often accompanied by chronic pain. Current therapies are successful in fewer than half of cases and often require grafting of a nerve from another part of the body.  Dr James Phillips, UCL School of Pharmacy, and his team at... read more
  We are delighted to announce that Oracle Corporation (NYSE: ORCL) has completed the acquisition of Grapeshot Limited. Since 2014, the Albion VCTs have invested a total of £2.9m in the business and on the assumption that the full escrow is received, the exit  represents a return of c.10x for the Albion VCTs.     Grapeshot provides brand safety and pre-bid contextual solutions to over 5,000 of the world’s leading marketers. Each month, over 38 billion programmatic ad impressions are enhanced using Grapeshot’s Contextual Intelligence Platform in dozens of languages, and Grapeshot has grown... read more
Albion Capital, the leading independent investment manager, has led a £6.5 million Series A investment round in PayAsUGym (‘PAUG’), the online fitness marketplace, alongside existing co-investor Concentric and individual angels. The investment will be used to build the team, further enhance the product, grow the gym network and overall user base. PAUG enables gym users to access a national network of thousands of health and fitness clubs, pools, classes and spas, on a flexible pay-as-you-go, short-term pass or unlimited membership basis. The company has rapidly expanded its range of venues... read more
Orchard Therapeutics
  - Agreement strengthens Orchard’s position as a global leader in gene therapy for rare diseases - GSK takes 19.9% equity stake in Orchard and seat on board   GSK and Orchard Therapeutics today announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients. This acquisition strengthens Orchard’s position as a global leader in gene therapy for rare diseases. GSK will continue to invest in the development of its platform capabilities... read more
Social Impact Investing
Twenty-two leading financial services companies have so far pledged their commitment to help create a culture of social impact investing in the UK. The signatories which include Albion have pledged to work together to drive forward the key recommendations of the Advisory Group to Government on Social Impact investing. Earlier this month, The Prime Minister, Theresa May, asked Elizabeth Corley, vice chair of Allianz Global Investors, to lead an industry taskforce to progress the Advisory Group’s recommendations. The statement of support asked industry leaders to commit to specific goals... read more
Securities Note
We have closed our 2017/2018 VCT top up offers after successfully raising the £32m amount targeted. The offers, which launched on 6 September 2017, are fully subscribed across the five Albion VCTs participating in the fundraising. We will now focus on investing the money raised in technology-driven, high growth companies, with a particular emphasis on its sector specialisms in digital healthcare, automation, digital security and data analytics. Albion has expanded its presence in the technology sector significantly in recent years, with notable investments including Black Swan Data (... read more